Genetic insights support PARP1 as a mediator in the protective association of ATP-citrate lyase inhibitors with melanoma
Abstract ATP-citrate lyase (ACLY) inhibitors emerge as a promising anti-cancer strategy, yet their causal effects across various cancer types remain unclear. Here, we employ a drug-target Mendelian randomization (MR) approach using four cis-expression quantitative trait loci for blood ACLY gene expr...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | Communications Biology |
| Online Access: | https://doi.org/10.1038/s42003-025-07860-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849730844213641216 |
|---|---|
| author | Jiawen Lu Gloria Hoi-Yee Li Jingyi Hu Zhenqian Wang |
| author_facet | Jiawen Lu Gloria Hoi-Yee Li Jingyi Hu Zhenqian Wang |
| author_sort | Jiawen Lu |
| collection | DOAJ |
| description | Abstract ATP-citrate lyase (ACLY) inhibitors emerge as a promising anti-cancer strategy, yet their causal effects across various cancer types remain unclear. Here, we employ a drug-target Mendelian randomization (MR) approach using four cis-expression quantitative trait loci for blood ACLY gene expression as genetic instruments to mimic ACLY inhibition. We utilize genetic data from the eQTLGen consortium (N = 31,684) for ACLY expression, the deCODE study (N = 35,559) for plasma proteome, and large-scale cancer genome-wide association studies consortia (N from 49,708 to 417,127) to investigate the association of genetically mimicked ACLY inhibitors with 17 cancers and identify potential mediating proteins. Genetically proxied ACLY inhibition is strongly associated with reduced melanoma risk (odds ratio [95% confidence interval (CI)]: 0.85 [0.78, 0.92]) in a combined analysis of two independent outcome datasets. Proteome-wide MR screening 1517 plasma proteins identifies 3 proteins associated with melanoma, with Poly [ADP-ribose] polymerase 1 (PARP1) showing strong colocalization support. Mediation analysis further suggests PARP1 as a mediator in the protective effect of ACLY inhibition on melanoma (mediated proportion [95% CI]: 51.52% [5.45%, 97.58%]). Follow-up and validation analyses support the robustness of these results. This study illuminates the therapeutic potential of ACLY inhibition in melanoma, with PARP1 implicated as a potential mediator, offering avenues for targeted interventions. |
| format | Article |
| id | doaj-art-a68840a463f74e85962bba3af44efed3 |
| institution | DOAJ |
| issn | 2399-3642 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Communications Biology |
| spelling | doaj-art-a68840a463f74e85962bba3af44efed32025-08-20T03:08:44ZengNature PortfolioCommunications Biology2399-36422025-05-018111210.1038/s42003-025-07860-zGenetic insights support PARP1 as a mediator in the protective association of ATP-citrate lyase inhibitors with melanomaJiawen Lu0Gloria Hoi-Yee Li1Jingyi Hu2Zhenqian Wang3Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic UniversityDepartment of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic UniversityNational Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South UniversityDepartment of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic UniversityAbstract ATP-citrate lyase (ACLY) inhibitors emerge as a promising anti-cancer strategy, yet their causal effects across various cancer types remain unclear. Here, we employ a drug-target Mendelian randomization (MR) approach using four cis-expression quantitative trait loci for blood ACLY gene expression as genetic instruments to mimic ACLY inhibition. We utilize genetic data from the eQTLGen consortium (N = 31,684) for ACLY expression, the deCODE study (N = 35,559) for plasma proteome, and large-scale cancer genome-wide association studies consortia (N from 49,708 to 417,127) to investigate the association of genetically mimicked ACLY inhibitors with 17 cancers and identify potential mediating proteins. Genetically proxied ACLY inhibition is strongly associated with reduced melanoma risk (odds ratio [95% confidence interval (CI)]: 0.85 [0.78, 0.92]) in a combined analysis of two independent outcome datasets. Proteome-wide MR screening 1517 plasma proteins identifies 3 proteins associated with melanoma, with Poly [ADP-ribose] polymerase 1 (PARP1) showing strong colocalization support. Mediation analysis further suggests PARP1 as a mediator in the protective effect of ACLY inhibition on melanoma (mediated proportion [95% CI]: 51.52% [5.45%, 97.58%]). Follow-up and validation analyses support the robustness of these results. This study illuminates the therapeutic potential of ACLY inhibition in melanoma, with PARP1 implicated as a potential mediator, offering avenues for targeted interventions.https://doi.org/10.1038/s42003-025-07860-z |
| spellingShingle | Jiawen Lu Gloria Hoi-Yee Li Jingyi Hu Zhenqian Wang Genetic insights support PARP1 as a mediator in the protective association of ATP-citrate lyase inhibitors with melanoma Communications Biology |
| title | Genetic insights support PARP1 as a mediator in the protective association of ATP-citrate lyase inhibitors with melanoma |
| title_full | Genetic insights support PARP1 as a mediator in the protective association of ATP-citrate lyase inhibitors with melanoma |
| title_fullStr | Genetic insights support PARP1 as a mediator in the protective association of ATP-citrate lyase inhibitors with melanoma |
| title_full_unstemmed | Genetic insights support PARP1 as a mediator in the protective association of ATP-citrate lyase inhibitors with melanoma |
| title_short | Genetic insights support PARP1 as a mediator in the protective association of ATP-citrate lyase inhibitors with melanoma |
| title_sort | genetic insights support parp1 as a mediator in the protective association of atp citrate lyase inhibitors with melanoma |
| url | https://doi.org/10.1038/s42003-025-07860-z |
| work_keys_str_mv | AT jiawenlu geneticinsightssupportparp1asamediatorintheprotectiveassociationofatpcitratelyaseinhibitorswithmelanoma AT gloriahoiyeeli geneticinsightssupportparp1asamediatorintheprotectiveassociationofatpcitratelyaseinhibitorswithmelanoma AT jingyihu geneticinsightssupportparp1asamediatorintheprotectiveassociationofatpcitratelyaseinhibitorswithmelanoma AT zhenqianwang geneticinsightssupportparp1asamediatorintheprotectiveassociationofatpcitratelyaseinhibitorswithmelanoma |